MD is set to launch a new leadership team headed by Dr. Ersko Erskov, MD, MD’s director of the Center for Drug Evaluation and Research, and Dr. Daniela Vázquez-Sánchez, MD.

The team will be led by Drs.

Bowles and Erskin Bowles, MD and Drs Armani Kochen and Robert W. Pritzker, MD respectively.

Both Bowles served as director of clinical trials at the National Institutes of Health from 2006-2011, and in that capacity oversaw the launch of Phase 1 clinical trials for a new Alzheimer’s disease drug, niacinamide.

Bowlies served as NIH director for the last two years.

In a statement, Bowles said:The Bowles Institute will focus on leading the development and implementation of a robust and comprehensive interdisciplinary research and development program to drive the discovery, development, and commercialization of innovative, clinically applicable treatments for major health and disease disorders.

The Bowles Center will lead a multi-pronged effort to accelerate this mission.

Bowles is a former director of NIH, serving as the chief of the division that oversees the biomedical research and the NIH.

In the last year, he has directed the first phase of a Phase 2 study of an Alzheimer’s drug to test whether it could slow the progression of the disease, and he has led several large NIH clinical trials, including the pivotal Phase 1 study that launched the drug, pembrolizumab, which is in Phase 2 clinical trials.

Bowlies was previously the head of the National Cancer Institute’s Division of Biologicals Research and led the NIH-supported Phase 1 trials of a novel drug for the treatment of Alzheimer’s, known as Natalizumumab.

In 2014, Bowlies was appointed the new acting director of NCI’s Center for Clinical Trials.

He previously served as vice president and associate dean of the University of California, San Francisco.

In 2016, he was appointed as the new deputy director of National Institutes for Health, where he oversees the National Institute of Allergy and Infectious Diseases.

Bowls has been a director of pharmaceutical companies that have developed drugs for Alzheimer’s and other diseases, including AstraZeneca, Pfizer, Merck and Novartis.